MX2025004716A - Metodos de tratamiento del cancer con sotorasib - Google Patents

Metodos de tratamiento del cancer con sotorasib

Info

Publication number
MX2025004716A
MX2025004716A MX2025004716A MX2025004716A MX2025004716A MX 2025004716 A MX2025004716 A MX 2025004716A MX 2025004716 A MX2025004716 A MX 2025004716A MX 2025004716 A MX2025004716 A MX 2025004716A MX 2025004716 A MX2025004716 A MX 2025004716A
Authority
MX
Mexico
Prior art keywords
sotorasib
treating cancer
methods
patient
moderate
Prior art date
Application number
MX2025004716A
Other languages
English (en)
Spanish (es)
Inventor
Brett E Houk
Mason C Mccomb
Panli Cardona
Sandeep Dutta
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of MX2025004716A publication Critical patent/MX2025004716A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MX2025004716A 2022-10-24 2025-04-23 Metodos de tratamiento del cancer con sotorasib MX2025004716A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263418695P 2022-10-24 2022-10-24
PCT/US2023/035736 WO2024091463A1 (fr) 2022-10-24 2023-10-23 Méthodes de traitement du cancer par sotorasib

Publications (1)

Publication Number Publication Date
MX2025004716A true MX2025004716A (es) 2025-05-02

Family

ID=88839813

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2025004716A MX2025004716A (es) 2022-10-24 2025-04-23 Metodos de tratamiento del cancer con sotorasib

Country Status (11)

Country Link
EP (1) EP4608406A1 (fr)
JP (1) JP2025535477A (fr)
KR (1) KR20250092216A (fr)
CN (1) CN120091823A (fr)
AU (1) AU2023366820A1 (fr)
CL (1) CL2025001198A1 (fr)
IL (1) IL320448A (fr)
JO (1) JOP20250089A1 (fr)
MX (1) MX2025004716A (fr)
TW (1) TW202423431A (fr)
WO (1) WO2024091463A1 (fr)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY39673A (es) * 2021-03-17 2022-10-31 Amgen Inc Pauta posológica de sotorasib

Also Published As

Publication number Publication date
JP2025535477A (ja) 2025-10-24
JOP20250089A1 (ar) 2025-04-23
AU2023366820A1 (en) 2025-06-12
KR20250092216A (ko) 2025-06-23
TW202423431A (zh) 2024-06-16
CN120091823A (zh) 2025-06-03
CL2025001198A1 (es) 2025-08-01
WO2024091463A1 (fr) 2024-05-02
IL320448A (en) 2025-06-01
EP4608406A1 (fr) 2025-09-03

Similar Documents

Publication Publication Date Title
MX2025005489A (es) Uso de lumateperona para el tratamiento del trastorno bipolar ii
MX2022015695A (es) Medicina de camptotecina con alta unidad de conexion hidrofila y conjugado de la misma.
MX2020011653A (es) Métodos de tratamiento para el abuso de sustancias.
EP4706638A3 (fr) Méthodes de traitement de l'insuffisance cardiaque par administration d'omecamtiv mecarbil
MY201603A (en) Combination of dextromethorphan and bupropion for treating depression
MX2020008258A (es) Formulaciones pediátricas de niraparib y métodos de tratamiento pediátricos.
MY206999A (en) Treatment of hidradenitis suppurativa using jak inhibitors
MX2023002024A (es) Métodos de tratamiento con modulador de miosina.
MX2023001717A (es) Composiciones y metodos de agentes de la ruta del estres replicativo para el tratamiento del cancer.
MX2022012557A (es) Metodos de tratamiento de la enfermedad renal diabetica.
PH12021551235A1 (en) Elacestrant in combination with abemaciclib in women with breast cancer
MX2016011333A (es) Sistemas de administracion de farmaco y metodo para el tratamiento de cancer de vejiga con gemcitabina.
MX2019013862A (es) Terapia de combinacion.
MX2020001727A (es) Terapia de combinacion.
WO2020132560A3 (fr) Compositions et méthodes pour cancérothérapie
MX2021001832A (es) Conjugados para su uso en metodos de tratamiento del cancer.
MX2022014886A (es) Metodos de tratamiento del cancer positivo para her2 con tucatinib en combinacion con trastuzumab y una quimioterapia a base de oxaliplatino.
PH12021552977A1 (en) Methods of treating urinary system cancers
MX2021011289A (es) Composiciones que comprenden moduladores de isoenzima m2 muscular de piruvato cinasa pkm2 y metodos de tratamiento que usan las mismas.
MX2021001764A (es) Terapia de combinacion.
MX2025004716A (es) Metodos de tratamiento del cancer con sotorasib
PH12022553030A1 (en) Pharmaceutical formulations of abiraterone acetate and niraparib
MX2024005084A (es) Tratamientos administrados de manera subcutanea para enfermedad de parkinson avanzada.
ZA202201446B (en) Methods of treating multifocal cancer
WO2019241641A3 (fr) Méthodes de traitement du cancer